Medicine
Empliciti 300 mg powder for injection
Empliciti 300 mg powder for injection is a prescription medicine containing Elotuzumab for intravenous use, marketed by ER Squibb & Sons, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store EMPLICITI under refrigeration at 2°C to 8°C (36°F-46°F). Do not freeze…
Key facts
- Active ingredient (INN)
- Elotuzumab
- Brand
- Empliciti
- Strength
- 300 mg
- Dosage form
- Powder for injection
- Route
- Intravenous
- Packs
- 1 vial
- Marketing authorisation holder
- ER Squibb & Sons
- Manufacturer
- ER Squibb & Sons
- Origin register
- US FDA, United States
- Storage
- Store EMPLICITI under refrigeration at 2°C to 8°C (36°F-46°F). Do not freeze or shake.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01FX08 Elotuzumab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 30 November 2015
- Identifiers
- RxCUI 1726110, 1726115, 1726117 +1DailyMed set ID 80686b7e-f6f4-4154-b5c0-c846425e2d91NDC 0003-2291Application BLA761035
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, single-use in 1 carton / 1 injection, powder, lyophilized, for solution in 1 vial, single-use | 0003-2291-11 | ER Squibb & Sons | 30 November 2015 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Elotuzumab
Clinical summary
Elotuzumab is an SLAMF7-directed immunostimulatory antibody indicated in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior therapies, among other approved uses. MedsAcross supplies Elotuzumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about ElotuzumabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- EMPLICITI prescribing information (ER Squibb & Sons) · U.S. National Library of Medicine, DailyMed
- Empliciti: European public assessment report (EPAR) · European Medicines Agency
Need Empliciti 300 mg powder for injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.